Drug Hunter
Home > PF-06843195
oral PI3K_-selective kinase inhibitor prodrug
preclinical candidate for breast cancer
from mining of prior PI3K inh., SBDD, and opt.
J. Med. Chem., Dec. 24, 2020
Pfizer, San Diego, CA
Pfizer oral PI3ka-selective kinase inhibitor prodrug
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
December 2020
Molecules of the Month
01
January
02
February
03
March
04
April
05
May
06
June
07
July
08
August
09
September
10
October
11
November
12
December
MOTY Nominees
Molecule of the Year